These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29435197)

  • 21. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
    Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea.
    Kwon JH; Yoo SH; Nam SW; Kim HY; Kim CW; You CR; Choi SW; Cho SH; Han JY; Song DS; Chang UI; Yang JM; Lee SW; Lee HL; Han NI; Kim SH; Song MJ; Sung PS; Jang JW; Bae SH; Choi JY; Yoon SK
    J Med Virol; 2019 Jun; 91(6):1104-1111. PubMed ID: 30695109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
    Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
    J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.
    Iio E; Shimada N; Takaguchi K; Senoh T; Eguchi Y; Atsukawa M; Tsubota A; Abe H; Kato K; Kusakabe A; Miyaki T; Matsuura K; Matsunami K; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
    Hepatol Res; 2017 Nov; 47(12):1308-1316. PubMed ID: 28332272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
    Yu JH; Lee JI; Lee KS; Kim JK
    Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
    Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
    Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
    McPhee F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Yu ML; Ahn SH; Ishikawa H; Bhore R; Zhou N; Hernandez D; Mendez P; Kumada H
    Adv Ther; 2015 Jul; 32(7):637-49. PubMed ID: 26155891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
    Ikeda H; Watanabe T; Okuse C; Matsumoto N; Ishii T; Yamada N; Shigefuku R; Hattori N; Matsunaga K; Nakano H; Hiraishi T; Kobayashi M; Yasuda K; Yamamoto H; Yasuda H; Kurosaki M; Izumi N; Yotsuyanagi H; Suzuki M; Itoh F
    J Med Virol; 2017 Jan; 89(1):99-105. PubMed ID: 27329864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
    El-Khayat H; Kamal EM; Mahmoud H; Gomaa A; Ebeid B; Sameh Y; Hasseb A; El Raziky M; El Serafy M; Doss W; Esmat G; Fouad Y; Attia D
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):440-446. PubMed ID: 31688311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin.
    Fedorchenko SV; Martynovych T; Klimenko Z; Yanchenko V; Solianyk I
    J Viral Hepat; 2020 May; 27(5):548-551. PubMed ID: 31894886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.
    Uchida Y; Kouyama JI; Naiki K; Sugawara K; Inao M; Imai Y; Nakayama N; Mochida S
    Hepatol Res; 2016 Nov; 46(12):1234-1246. PubMed ID: 26878268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
    Wyles D; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Martin R; Afdhal NH; Kowdley KV; Lawitz E; Brainard DM; Miller MD; Mo H; Gane EJ
    J Hepatol; 2017 Apr; 66(4):703-710. PubMed ID: 27923693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors.
    Kanda T; Yasui S; Nakamura M; Suzuki E; Arai M; Ooka Y; Ogasawara S; Chiba T; Saito T; Haga Y; Takahashi K; Sasaki R; Wu S; Nakamoto S; Tawada A; Maruyama H; Imazeki F; Kato N; Yokosuka O
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28441362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir.
    Safadi R; Noviello S; Boparai N; McPhee F
    Clin Case Rep; 2016 Jul; 4(7):653-6. PubMed ID: 27386121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation.
    Omichi K; Akamatsu N; Mori K; Togashi J; Arita J; Kaneko J; Hasegawa K; Sakamoto Y; Kokudo N
    Hepatol Res; 2017 Oct; 47(11):1093-1101. PubMed ID: 27875005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.
    Gastroenterol Hepatol (N Y); 2014 Jun; 10(6 Suppl 2):1-19. PubMed ID: 26180519
    [No Abstract]   [Full Text] [Related]  

  • 39. Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
    Kim KA; Lee S; Park HJ; Jang ES; Lee YJ; Cho SB; Kim YS; Kim IH; Lee BS; Chung WJ; Ahn SH; Kim S; Jeong SH
    Clin Mol Hepatol; 2023 Apr; 29(2):496-509. PubMed ID: 36880209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
    Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS
    Elife; 2023 Jan; 12():. PubMed ID: 36622106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.